ARA-290 (cibinetide) is an investigational peptide, not an approved medicine. The amounts below are the protocols used in published clinical trials, described for education. They are not medically established for self-use and are not a personal plan.
Overview
There is no approved ARA-290 dose — but unlike most research peptides, its numbers come from actual clinical trials rather than forum lore. Across three published randomized studies, ARA-290 was given at 2 mg intravenously three times a week, or 1–8 mg by subcutaneous injection once daily, always for defined periods of about four weeks, in patients with diagnosed neuropathic disease. The most commonly cited figure, 4 mg daily, is the dose that performed best on objective nerve measures — and, notably, a higher dose did not do better.
Trial protocols, study by study
- 2012 sarcoidosis pilot: 2 mg intravenously, three times weekly, for 4 weeks (Molecular Medicine 2012).
- 2014 diabetes trial: 4 mg subcutaneously, once daily, for 28 days, with a 28-day observation follow-up (Molecular Medicine 2014).
- 2017 dose-ranging trial: 1, 4, or 8 mg subcutaneously, once daily, for 28 days, versus placebo (Investigative Ophthalmology & Visual Science 2017).
Three features distinguish these from community-style peptide use: fixed doses with no escalation, strictly time-limited courses, and continuous clinical and laboratory monitoring. Each trial also built in a post-treatment observation window — the diabetes study followed participants for 28 further days after the last dose — because a repair-signaling compound's effects (and any harms) can outlast the dosing period. That follow-up structure is part of the protocol, not an afterthought.
The dose-response curve was not linear
The dose-ranging trial produced a result worth understanding before assuming more is better: the 4 mg dose improved corneal nerve-fiber measures significantly, while the 8 mg dose did not. Inverted-U dose responses like this are common with tissue-repair signaling, and they undercut the intuition — baked into most community dosing habits — that doubling a dose doubles an effect. For this compound, the best-studied dose is the middle one, and nobody knows why with certainty.
Administration and preparation
In trials, ARA-290 was given parenterally — IV in the earliest study, subcutaneous injection in the later ones. Gray-market material is typically a lyophilized powder requiring reconstitution, where the added diluent volume sets the concentration and syringe units must be read as volume; the peptide calculator covers that arithmetic. Its circulating half-life is short — the design assumes brief receptor engagement triggers longer-lasting repair signaling, another reason simple dose intuitions fail here: the trials dosed once daily not to maintain constant blood levels, as with long-acting metabolic peptides, but to deliver repeated short signaling pulses to a receptor that assembles in injured tissue.
Why oversight matters
The trial numbers describe supervised research in specific diseases (sarcoidosis and diabetic small-fiber neuropathy) over four weeks. They say nothing about longer use, healthy people, or unmonitored settings, and no label exists to fill the gap — the development program ended before producing one. A clinician can screen, monitor, and judge whether any of this applies to an individual; a trial table cannot. See the main ARA-290 reference page and the safety guide for the rest of the picture.